Navigation Links
Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Date:9/6/2007

BARCELONA, Spain, Sept. 6 /PRNewswire/ -- Elekta, a world leader in radiation oncology and non-invasive neurosurgery solutions, will showcase the latest advances in radiotherapy, stereotactic radiosurgery and clinical workflow solutions at the European Society of Therapeutic Radiation Oncologists (ESTRO) 2007 meeting in Barcelona, Spain, September 8-13. More than 2,000 physicists, radiotherapists, oncologists and other health care professionals are expected at the Ninth Biennial ESTRO meeting on Physics and Radiation Technology for Clinical Radiotherapy at the Palau de Congresos de Catalunya. Monday, September 10 at 11 a.m. CEST, Tomas Puusepp, President and CEO of Elekta, will unveil an innovative new radiation therapy system in the Elekta booth (No. 4-6) that will help expand the ability to provide precision radiation therapy and bring advanced cancer treatment to many more patients around the world.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

"This new product is yet another advancement as we continually expand and enhance our portfolio of cancer treatment solutions to offer more effective and efficient options to a broader range of health care providers, regardless of size," says Puusepp. "We are pleased to present this along with our other innovations that help optimize treatment efficacy and workflow."

Broad range of solutions on display

Elekta's theme at ESTRO this year is "Moving forward together." For the first time at ESTRO, Elekta will showcase the entire Elekta family of products, services, and companies, including Elekta's flagship products together with integrated product innovations from past Elekta company acquisitions. Elekta will have on display product solutions for providing precise radiation therapy, image guidance, stereotactic neuroscience, functional mapping and information systems management.

Elekta wi
'/>"/>

SOURCE Elekta, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BIO provides forum for Wisconsin to showcase strengths
2. EForum to showcase Southeast Wisconsin tech entrepreneurship
3. Life-sciences conference showcases capital ideas of Wisconsin
4. Modine showcases CO2 cooled Jeep
5. Johnson Controls To Showcase New Technologies for the Auto Industry
6. Conference to Showcase Regions Biotech Companies
7. Pilot fund brings capital to Eau Claire area innovations
8. Wisconsin state agencies commended for digital innovations
9. Oshkoshs Pierce Security Vehicle Ranked in top 100 Technological Innovations for 2003
10. Merge unveils next-generation imaging-informatics product
11. Merge unveils updated medical imaging software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... Asian Automatic patient billing report defines and segments the ... The Automatic patient billing market in Asia is estimated ... a developing CAGR of 7.2% from 2013 to 2018. ... patient billing market, to get an idea of the ... the segmentation of this market in the same region, ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... 2010 , - Proposed recommended cash acquisition of specialty gastrointestinal, ... equity purchase price of, EUR428 million in cash. ... date, Movetis held EUR100 million in cash; based on this the, ... - Strong strategic fit with Shire,s growing core GI business; ...
... innovation that can help scientists observe a reaction moving at ... spatial resolution, is a feat some would say is nearly ... scientists who developed the dynamic transmission electron microscope (DTEM). ... of scientific phenomena while it,s happening has earned it one ...
... EAST NORRITON, Pa. , Aug. 2 Tengion Inc. (Nasdaq: ... A. Brian Davis to the position of Chief Financial Officer. ... a biopharmaceutical company using enzymatic technologies to develop improved protein therapeutics. At ... personnel at three sites.  , , ...
Cached Biology Technology:Shire Proposes to Expand Specialist Gastrointestinal Portfolio 2Shire Proposes to Expand Specialist Gastrointestinal Portfolio 3Shire Proposes to Expand Specialist Gastrointestinal Portfolio 4Shire Proposes to Expand Specialist Gastrointestinal Portfolio 5Shire Proposes to Expand Specialist Gastrointestinal Portfolio 6Shire Proposes to Expand Specialist Gastrointestinal Portfolio 7Shire Proposes to Expand Specialist Gastrointestinal Portfolio 8Shire Proposes to Expand Specialist Gastrointestinal Portfolio 9Livermore's DTEM earns innovation award from Microscopy Today 2Tengion Appoints A. Brian Davis Chief Financial Officer 2
(Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... With land degradation in dryland regions continuing to ... agreed on scientist-recommended indicators for monitoring and assessing ... The landmark agreement was reached after two weeks ... ministers attending the Ninth Session of the Conference ...
... October 7, 2009 H2 Blocker drugs, such as Famotidine, ... (heartburn), pose no significant risks for the fetus according to ... of the Negev. The study published in the ... safety of the fetus when H2 blocker drugs are ...
... look for clues about therapies and cures for life-threatening ... logical to do so. But the decision as to ... provides a unique ethical conundrum, says a Tel Aviv ... journal Science , co-authored by colleagues from The ...
Cached Biology News:Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers 2Keeping DNA 'all in the family' 2Keeping DNA 'all in the family' 3
ID clarifier: platform...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
... Tetrad 2 thermal cycler accommodates a ... heat-pump assemblies), which hold different types ... computer drives an advanced graphical interface ... lid temperatures. Peltier heat pumps, built ...
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
Biology Products: